Cocaine- and amphetamine-related transcript is involved in the orexigenic effect of endogenous anandamide.
Endocannabinoids acting at CB1 cannabinoid receptors (CB1) increase appetite. In view of the predominant presynaptic localization of CB1 in the brain, we tested the hypothesis that the orexigenic effect of endocannabinoids involves inhibition of the release of a tonically active anorexigenic mediator, such as the peptide product of the cocaine- and amphetamine-related transcript (CART). The CB1 antagonist rimonabant inhibited food intake in food-restricted wild-type mice, but not in their CART-deficient littermates. Mice deficient in fatty acid amide hydrolase (FAAH), the enzyme responsible for the in vivo metabolism of the endocannabinoid anandamide, have reduced levels of CART-immunoreactive nerve fibers and terminals in several brain regions implicated in appetite control, including the arcuate, dorsomedial and periventricular nuclei of the hypothalamus, the amygdala, the bed nucleus of the stria terminalis and the nucleus accumbens, and treatment of FAAH(-/-) mice with rimonabant, 3 mg/kg/day for 7 days, increased CART levels toward those seen in FAAH(+/+) wild-type controls. In contrast, no difference in the density of CART-immunoreactive fibers was observed in the median eminence and the paraventricular nucleus of FAAH(+/+) and FAAH(-/-) mice. Acute treatment of wild-type mice with the cannabinoid agonist HU-210 resulted in elevated CART levels in the dorsomedial nucleus and the shell portion of the nucleus accumbens. These observations are compatible with CART being a downstream mediator of the CB1-mediated orexigenic effect of endogenous anandamide.
Osei-Hyiaman
Douglas
D
Section on Neuroendocrinology, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD 20892, USA.
Depetrillo
Michael
M
Harvey-White
Judith
J
Bannon
Anthony W
AW
Cravatt
Benjamin F
BF
Kuhar
Michael J
MJ
Mackie
Ken
K
Palkovits
Miklós
M
Kunos
George
G
D000818:Animals; D001066:Appetite / Q000187:drug effects / Q000502:physiology*; D001095:Arachidonic Acids / Q000502:physiology*; D001921:Brain / Q000648:ultrastructure; D001923:Brain Chemistry; D063385:Cannabinoid Receptor Modulators / Q000032:analysis / Q000502:physiology*; D013759:Dronabinol / Q000031:analogs & derivatives / Q000494:pharmacology; D004435:Eating / Q000187:drug effects; D063388:Endocannabinoids; D005508:Food Deprivation; D007150:Immunohistochemistry; D051379:Mice; D018345:Mice, Knockout; D009411:Nerve Endings / Q000737:chemistry; D009412:Nerve Fibers / Q000737:chemistry; D009419:Nerve Tissue Proteins / Q000032:analysis / Q000172:deficiency / Q000502:physiology*; D010880:Piperidines / Q000494:pharmacology; D053284:Polyunsaturated Alkamides; D011720:Pyrazoles / Q000494:pharmacology; D043884:Receptor, Cannabinoid, CB1 / Q000032:analysis / Q000037:antagonists & inhibitors / Q000502:physiology*; D000077285:Rimonabant; D000098882:Cocaine- and Amphetamine-Regulated Transcript Protein
D001095:Arachidonic Acids; D063385:Cannabinoid Receptor Modulators; D063388:Endocannabinoids; D009419:Nerve Tissue Proteins; D010880:Piperidines; D053284:Polyunsaturated Alkamides; D011720:Pyrazoles; D043884:Receptor, Cannabinoid, CB1; D000098882:Cocaine- and Amphetamine-Regulated Transcript Protein; D013759:Dronabinol; C062018:HU 211; D000077285:Rimonabant; C078814:anandamide